全文获取类型
收费全文 | 2056篇 |
免费 | 175篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 38篇 |
儿科学 | 63篇 |
妇产科学 | 49篇 |
基础医学 | 265篇 |
口腔科学 | 36篇 |
临床医学 | 140篇 |
内科学 | 360篇 |
皮肤病学 | 68篇 |
神经病学 | 274篇 |
特种医学 | 68篇 |
外科学 | 316篇 |
综合类 | 40篇 |
一般理论 | 1篇 |
预防医学 | 106篇 |
眼科学 | 68篇 |
药学 | 183篇 |
中国医学 | 8篇 |
肿瘤学 | 152篇 |
出版年
2023年 | 14篇 |
2022年 | 43篇 |
2021年 | 57篇 |
2020年 | 47篇 |
2019年 | 47篇 |
2018年 | 68篇 |
2017年 | 42篇 |
2016年 | 33篇 |
2015年 | 48篇 |
2014年 | 61篇 |
2013年 | 83篇 |
2012年 | 124篇 |
2011年 | 139篇 |
2010年 | 66篇 |
2009年 | 50篇 |
2008年 | 124篇 |
2007年 | 132篇 |
2006年 | 123篇 |
2005年 | 84篇 |
2004年 | 93篇 |
2003年 | 76篇 |
2002年 | 69篇 |
2001年 | 59篇 |
2000年 | 59篇 |
1999年 | 37篇 |
1998年 | 14篇 |
1997年 | 11篇 |
1996年 | 13篇 |
1995年 | 17篇 |
1994年 | 11篇 |
1993年 | 8篇 |
1992年 | 28篇 |
1991年 | 46篇 |
1990年 | 40篇 |
1989年 | 30篇 |
1988年 | 28篇 |
1987年 | 28篇 |
1986年 | 21篇 |
1985年 | 16篇 |
1984年 | 18篇 |
1983年 | 9篇 |
1981年 | 9篇 |
1980年 | 9篇 |
1979年 | 8篇 |
1978年 | 9篇 |
1977年 | 11篇 |
1976年 | 7篇 |
1975年 | 8篇 |
1970年 | 7篇 |
1968年 | 7篇 |
排序方式: 共有2235条查询结果,搜索用时 15 毫秒
81.
Healthcare systems are increasingly recognised as complex, in which a range of non-linear and emergent behaviours occur. China’s healthcare system is no exception. The hugeness of China, and the variation in conditions in different jurisdictions present very substantial challenges to reformers, and militate against adopting one-size-fits-all policy solutions. As a consequence, approaches to change management in China have frequently emphasised the importance of sub-national experimentation, innovation, and learning. Multiple mechanisms exist within the government structure to allow and encourage flexible implementation of policies, and tailoring of reforms to context. These limit the risk of large-scale policy failures and play a role in exploring new reform directions and potentially systemically-useful practices. They have helped in managing the huge transition that China has undergone from the 1970s onwards. China has historically made use of a number of mechanisms to encourage learning from innovative and emergent policy practices. Policy evaluation is increasingly becoming a tool used to probe emergent practices and inform iterative policy making/refining. This paper examines the case of a central policy research institute whose mandate includes evaluating reforms and providing feedback to the health ministry. Evaluation approaches being used are evolving as Chinese research agencies become increasingly professionalised, and in response to the increasing complexity of reforms. The paper argues that learning from widespread innovation and experimentation is challenging, but necessary for stewardship of large, and rapidly-changing systems. 相似文献
82.
Development and validation of a sensitive HPLC method for the determination of lisinopril in human plasma after derivatization with 4-fluoro-7-nitro-2,1,3-benzoxadiazole
下载免费PDF全文
![点击此处可从《中国药学》网站下载免费的PDF全文](/ch/ext_images/free.gif)
In this study, we developed a simple and sensitive HPLC method for the determination of lisinopril in human plasma. The sample clean-up was carried out by solid-phase extraction (SPE) using a cation-exchange (Strata-SCX®) extraction cartridge. After a pre-column derivatization with 4-fluoro-7-nitro-2,1,3-benzoxadiazole, the reaction mixture was analyzed on an Agilent Zorbax SB®-C18 (150 mm×4.6 mm, 5 μm). The flow rate was set at 1.0 mL/min. Fluorescence detection was performed at an excitation wavelength of 470 nm and an emission wavelength of 530 nm. The mobile phase consisted of a mixture of methanol and 0.02 M sodium dihydrogen phosphate (pH = 3.0, 60:40, v/v). The average extraction recovery of lisinopril and fluvoxamine (internal standard) was >85%. The method exhibited a linear calibration curve over the concentration range of 1–1000 ng/mL with a correlation coefficient (r2) of ≥0.98 and a limit of quantification (LOQ) equal to 2 ng/mL. The within-run and between-run precisions were satisfactory with an RSD of 3.8%–13.7% (accuracy: from 95.0% to 96.4%) and 4.273%–14.3% (accuracy: from 94.4% to 98.5%), respectively. 相似文献
83.
84.
Silky Bedi Shah A. Khan Majed M. AbuKhader Perwez Alam Nasir A. Siddiqui Asif Husain 《Saudi Pharmaceutical Journal》2018,26(6):755-763
The mortality rate in patients suffering from non-small cell lung cancer (NSCLC) is quite high. This type of cancer mainly occurs due to rearrangements in the anaplastic lymphoma kinase (ALK) gene which leads to form an oncogene of fused gene NPM-ALK. Brigatinib is recently approved by FDA in April 2017 as a potent tyrosine kinase inhibitor (TKI) for the NSCLC therapy. In the present scenario, it is no less than a wonder drug because it is indicated for the treatment of advanced stages of metastatic ALK positive NSCLC, a fatal disease to overcome the resistance of various other ALK inhibitors such as crizotinib, ceritinib and alectinib. In addition to ALK, it is also active against multiple types of kinases such as ROS1, Insulin like growth factor-1Receptor and EGFR. It can be synthesized by using N-[2-methoxy-4-[4-(dimethylamino) piperidin-1-yl] aniline] guanidine and 2,4,5-trichloropyrimidine respectively in two different ways. Its structure consists of mainly dimethylphosphine oxide group which is responsible for its pharmacological activity. It is active against various cell lines such as HCC78, H2228, H23, H358, H838, U937, HepG2 and Karpas- 299. Results of ALTA (ALK in Lung Cancer Trial of AP26113) phase ½ trial shows that 90?mg of brigatinib for 7?days and then 180?mg for next days is effective in the treatment of NSCLC. Brigatinib has been shown to have favorable risk benefit profile and is a safer drug than the available cytotoxic chemotherapeutic agents. In comparison to other FDA approved drugs for the same condition, it causes fewer minor adverse reactions which can be easily managed either by changing the dose or by providing good supportive care. This article is intended to provide readers with an overview of chemistry, pharmacokinetic, pharmacodynamic and safety profile of brigatinib, which addresses an unmet medical need. 相似文献
85.
86.
Marcus R. Pereira Sumit Mohan David J. Cohen Syed A. Husain Geoffrey K. Dube Lloyd E. Ratner Selim Arcasoy Meghan M. Aversa Luke J. Benvenuto Darshana M. Dadhania Sandip Kapur Lorna M. Dove Robert S. Brown Russell E. Rosenblatt Benjamin Samstein Nir Uriel Maryjane A. Farr Michael Satlin Catherine B. Small Thomas J. Walsh Rosy P. Kodiyanplakkal Benjamin A. Miko Justin G. Aaron Demetra S. Tsapepas Jean C. Emond Elizabeth C. Verna 《American journal of transplantation》2020,20(7):1800-1808
Solid organ transplant recipients may be at a high risk for SARS‐CoV‐2 infection and poor associated outcomes. We herein report our initial experience with solid organ transplant recipients with SARS‐CoV‐2 infection at two centers during the first 3 weeks of the outbreak in New York City. Baseline characteristics, clinical presentation, antiviral and immunosuppressive management were compared between patients with mild/moderate and severe disease (defined as ICU admission, intubation or death). Ninety patients were analyzed with a median age of 57 years. Forty‐six were kidney recipients, 17 lung, 13 liver, 9 heart, and 5 dual‐organ transplants. The most common presenting symptoms were fever (70%), cough (59%), and dyspnea (43%). Twenty‐two (24%) had mild, 41 (46%) moderate, and 27 (30%) severe disease. Among the 68 hospitalized patients, 12% required non‐rebreather and 35% required intubation. 91% received hydroxychloroquine, 66% azithromycin, 3% remdesivir, 21% tocilizumab, and 24% bolus steroids. Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) and 37 (54%) were discharged. In this initial cohort, transplant recipients with COVID‐19 appear to have more severe outcomes, although testing limitations likely led to undercounting of mild/asymptomatic cases. As this outbreak unfolds, COVID‐19 has the potential to severely impact solid organ transplant recipients. 相似文献
87.
Descriptive assessment on diabetic retinopathy screening in an awareness programme in Malaysia
下载免费PDF全文
![点击此处可从《国际眼科》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Nor Fariza Ngah Nor Asiah Muham Zalifa Zakiah Asnir Roslin Azni Abdul Aziz Zaidah Mhad Kassim Siti Aishah Sahar Nor Azita Ahmad Tarmidzi Chan Li Yen Rosmawati Uthman Narjis Satar Noor Zahirah Husain Azian Adnan John Mathen Kayalakakathu Bariyah Kadas Noor Suriani Moham Shaiful Azlan Kassim 《国际眼科》2020,13(11):1808-1813
88.
Asif Husain Priyanka Ahuja M. Shaharyar Aftab Ahmad Ibraheem Ahmed I. Mkhalid M. M. Alam M. Akhter M. S. Zaman 《Medicinal chemistry research》2014,23(3):1077-1083
An ester-based mutual prodrug (aceclofenac–paracetamol; AC-PR) was synthesized (one-pot method) with an aim of improving the therapeutic index through prevention of gastrointestinal irritation and bleeding that is associated with aceclofenac. The release of aceclofenac and paracetamol from the ester prodrug (AC-PR) was studied by reverse phase HPLC in hydrochloric acid buffer (pH 1.2), phosphate buffer (pH 7.4), 80 % v/v human plasma, 10 % w/v rat intestinal homogenate and 10 % w/v rat liver homogenate (pH 7.4). The prodrug showed negligible hydrolysis at pH 1.2 as compared to pH 7.4, suggesting that very less of the prodrug would hydrolyze in stomach, but would release the parent drugs at pH 7.4 in adequate amounts. The prodrug showed enhanced anti-inflammatory activity and significant protection against acetic acid-induced writhings (analgesic activity) as compared to that of aceclofenac. Further, the prodrug produced reduced number of ulcers as compared to that of the parent drug. These results suggest that the synthesized mutual prodrug (AC-PR) is better in terms of activity and GIT toxicity than the parent drug. 相似文献
89.
90.
Subodh Verma MD Udi Fainberg MD Mansoor Husain MD Søren Rasmussen PhD Lars Rydén MD Maria Sejersten Ripa MD John B. Buse MD 《Diabetes, obesity & metabolism》2021,23(7):1677-1680
In the REWIND trial, dulaglutide reduced cardiovascular (CV) risk versus placebo in patients with type 2 diabetes in both the “established CV disease” (CVD) and “CV risk factor” subgroups. The SUSTAIN 6 and PIONEER 6 trials of semaglutide used different criteria for established CVD from those used in REWIND. The present post hoc analysis assessed the effect of semaglutide on major adverse CV events (MACE) in a pooled population of SUSTAIN 6 and PIONEER 6 patients, re-categorized into CV risk subgroups using the REWIND CVD criteria. In the pooled analysis (n = 6480), a lower percentage of patients were in the established CVD subgroup, when using the REWIND CVD criteria, compared with the original trial CVD criteria (66.5% vs. 83.8%, respectively). After re-categorization, the risk of MACE was significantly lower with semaglutide versus placebo in the established CVD subgroup (hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.59, 0.92) and nonsignificantly lower in the CV risk factor subgroup (HR 0.84, 95% CI 0.55, 1.28) (P-interaction = 0.60). These results suggest that the CV effects of semaglutide may extend to patients with type 2 diabetes across the CV risk continuum. 相似文献